LEUVEN, Belgium, December 6, 2013 /PRNewswire via COMTEX/ -- Dr Staf Van Reet appointed as new Chairman of the Board
ThromboGenics NV (euronext brussels:THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that Prof Désiré Collen has decided to retire as Chairman and board member. Dr Staf Van Reet, currently a member of the ThromboGenics Board and a seasoned biopharma veteran, has been appointed Chairman of ThromboGenics.
Help employers find you! Check out all the jobs and post your resume.
